• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Alnylam Pharmaceuticals (ALNY)

Common Shares
Sell: $385.00|Buy: $399.13|Change: 6.05 (-1.52%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Address

675 West Kendall Street
Henri A. Termeer Square
Cambridge
MA
USA
02142

Telephone

+1 617 6824340

Website

https://www.alnylam.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Alnylam Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20262026-10-30T08:30:00
Alnylam Pharmaceuticals Inc Third Quarter Earnings Results for 20262026-10-30T00:00:00
Alnylam Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20262026-07-31T08:30:00
Alnylam Pharmaceuticals Inc Second Quarter Earnings Results for 20262026-07-31T00:00:00
Alnylam Pharmaceuticals Inc Annual General Meeting for 20262026-05-08T08:30:00
Alnylam Pharmaceuticals Inc First Quarter Earnings Conference Call for 20262026-05-01T08:30:00
Alnylam Pharmaceuticals Inc First Quarter Earnings Results for 20262026-05-01T00:00:00
Alnylam Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20252026-02-13T08:30:00
Alnylam Pharmaceuticals Inc Fourth Quarter Earnings Results for 20252026-02-13T00:00:00
Alnylam Pharmaceuticals Inc Annual Report for 20252026-02-13T00:00:00

Previous key dates

NameKey Date
Jefferies Global Healthcare Conference2025-11-19T06:30:00
UBS Global Healthcare Conference2025-11-10T10:15:00
Alnylam Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20252025-10-30T08:30:00
Alnylam Pharmaceuticals Inc Third Quarter Earnings Result for 20252025-10-30T00:00:00
Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum2025-09-23T08:00:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-10T12:17:00
Citi's 2025 Biopharma Back to School Conference2025-09-03T13:45:00
Alnylam Webcast to Discuss Results from the KARDIA-3 Phase 2 Study of Zilebesiran2025-08-30T13:00:00
Canaccord Genuity 45th Annual Growth Conference2025-08-12T08:00:00
Alnylam Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20252025-07-31T08:30:00
Alnylam Pharmaceuticals Inc Second Quarter Earnings Results for 20252025-07-31T00:00:00
Goldman Sachs 46th Annual Global Healthcare Conference2025-06-09T09:20:00
BofA Securities 2025 Health Care Conference2025-05-14T11:20:00
Alnylam Pharmaceuticals Inc Annual General Meeting for 20252025-05-08T08:30:00
Alnylam Pharmaceuticals Inc First Quarter Earnings Conference Call for 20252025-05-01T08:30:00
Alnylam Pharmaceuticals Inc First Quarter Earnings Result for 20252025-05-01T00:00:00
Needham 24th Annual Virtual Healthcare Conference2025-04-08T11:45:00
Stifel 2025 Virtual CNS Forum2025-03-18T15:00:00
Alnylam Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20242025-02-13T08:30:00
Alnylam Pharmaceuticals Inc Fourth Quarter Earnings Result for 20242025-02-13T00:00:00
Alnylam Pharmaceuticals Inc Annual Report for 20242025-02-13T00:00:00
43rd Annual J.P. Morgan Healthcare Conference2025-01-13T12:45:00
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference2024-12-05T11:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.